Highly active antiretroviral therapies (HAART) is incapable of fully eradicating virus within an adult patient, due to the persistence of latently infected resting CD4+ T lymphocytes and infected macrophages and monocytes, which may produce low levels of viremia without dying. Recently, there has been a growing interest in using gene therapy as an alternative to HAART, particularly with the recent breakthrough of the Berlin patient, who was """"""""functionally cured"""""""" of HIV after receiving an allogeneic bone marrow transplant with CCR5-defective hematopoietic stem cells. Indeed, we have conducted the only clinical trial to date to test an anti-HIV RNAi therapeutic, which required the ex vivo delivery of a lentiviral vector in autologous CD34+ hematopoietic stem cells for patients with AIDS-related lymphoma. However, for RNAi-based therapeutics to become available for the vast majority of HIV patients, alternative systemic delivery methods must be developed. In this project, we will test three promising methods for delivering anti-HIV siRNAs: an anti-gp120 RNA aptamer-siRNA conjugate for targeted delivery into cells actively infected with HIV;an anti-CD4 RNA aptamer-siRNA conjugate for targeted delivery into CD4+ T cells and macrophages;and a cationic PAMAM dendrimer-siRNA nanoparticle for systemic delivery.
For Aim 1, we will elucidate the molecular interactions between the anti-gp120 aptamer and HIV gp120 protein using surface plasmon resonance, X-ray crystallography, and electron microscopy.
In Aim2 of this project, we will use positron emission tomography and near-infrared fluorescence imaging to measure the dose- dependent biodistribution and whole-body clearance of our RNA-based therapeutics in a humanized mouse model.
In Aim 3, we will conduct a series of in vivo experiments in HIV-infected humanized mice to test the efficacy of individual and combination RNA-based therapies. These experiments will test siRNAs that target endogenous genes required for HIV infection (prophylactic and entry inhibitor siRNAs), mechanisms required for the persistence of latency (anti-latency siRNAs), and genes required for cell survival (cytotoxic siRNAs). Hence, we will test a comprehensive, RNA-based """"""""shock and kill"""""""" strategy that aims to purge the latent reservoir, eliminate the cells actively infected with HIV, and protect cells from new infection. In addition to standard assays for detecting HIV viremia, we will use droplet digital PCR to measure the levels of integrated provirus in treated and non-treated animals. In summary, this project represents an innovative approach for suppressing and potentially eradicating HIV infection. Moreover, the aims of this pre-clinical study will establish an important benchmark for evaluating RNAi- based therapy as a treatment for HIV.

Public Health Relevance

Recent advances in RNAi-based drugs have broadened the scope of therapeutic targets for a variety of human disease. We have designed a new systemic delivery approach for a cocktail of anti-HIV siRNAs using chemically synthesized, ligand-specific RNA aptamers or cationic PAMAM dendrimer nanoparticles. We will test these RNA therapies in a pre-clinical investigation in humanized mice by monitoring the biodistribution, whole-body clearance, and off-target toxicity. In addition, we will perform functional analyses in HIV-infecte mice to examine the potential eradication of latent reservoirs and prophylactic treatment of siRNAs pre- and post-HIV challenge.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
2R01AI029329-24A1
Application #
8731505
Study Section
AIDS Discovery and Development of Therapeutics Study Section (ADDT)
Program Officer
Voulgaropoulou, Frosso
Project Start
1996-07-03
Project End
2019-01-31
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
24
Fiscal Year
2014
Total Cost
$588,756
Indirect Cost
$238,306
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Dao, Phuong; Hoinka, Jan; Takahashi, Mayumi et al. (2016) AptaTRACE Elucidates RNA Sequence-Structure Motifs from Selection Trends in HT-SELEX Experiments. Cell Syst 3:62-70
Takahashi, Mayumi; Wu, Xiwei; Ho, Michelle et al. (2016) High throughput sequencing analysis of RNA libraries reveals the influences of initial library and PCR methods on SELEX efficiency. Sci Rep 6:33697
Bobbin, Maggie L; Rossi, John J (2016) RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise? Annu Rev Pharmacol Toxicol 56:103-22
Zhou, Jiehua; Rossi, John J (2016) Evolution of Cell-Type-Specific RNA Aptamers Via Live Cell-Based SELEX. Methods Mol Biol 1421:191-214
Cui, Qi; Yang, Su; Ye, Peng et al. (2016) Downregulation of TLX induces TET3 expression and inhibits glioblastoma stem cell self-renewal and tumorigenesis. Nat Commun 7:10637
Chen, Chao; Posocco, Paola; Liu, Xiaoxuan et al. (2016) Mastering Dendrimer Self-Assembly for Efficient siRNA Delivery: From Conceptual Design to In Vivo Efficient Gene Silencing. Small 12:3667-76
Daniels, Sylvanne M; Sinck, Lucile; Ward, Natalie J et al. (2015) HIV-1 RRE RNA acts as an RNA silencing suppressor by competing with TRBP-bound siRNAs. RNA Biol 12:123-35
Petz, Lawrence D; Burnett, John C; Li, Haitang et al. (2015) Progress toward curing HIV infection with hematopoietic cell transplantation. Stem Cells Cloning 8:109-16
Madu, Ikenna G; Li, Shirley; Li, Baozong et al. (2015) A Novel Class of HIV-1 Antiviral Agents Targeting HIV via a SUMOylation-Dependent Mechanism. Sci Rep 5:17808
Zhou, Jiehua; Satheesan, Sangeetha; Li, Haitang et al. (2015) Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity. Chem Biol 22:379-90

Showing the most recent 10 out of 152 publications